Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors

Stock Information for Longeveron Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Longeveron Inc.

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease
Longeveron® Appoints Marie Washburn as Chief Financial Officer
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Longeveron to Present at BIO International Convention 2026
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.